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Abstract: 
Ocular Effects of Clinical Antibiotic Usage 
Bryan E. Lallathin, B.S. 
Brian K. Mitchell, B.S. 
Salisa K. Williams, 0.0. 
With the passing of laws allowing the usage of therapeutic pharmaceutical agents (TPAs) by optometrists, 
information to provide guidelines to optometrists and other medical practitioners in treating patients with 
ocular bacterial infections is needed. The effects of the gentamicin, an aminoglycoside, on the corneal epithelium 
of human subjects using clinically acceptable and recommended doses was observed. 
Introduction: 
A patient arrives in your office with complaints that their eyes feel gritty and that their lids have been 
sticking together upon waking in the morning. After thorough examination, you diagnose simple conjunctivitis. 
You then prescribe 3 mg/ml solution of gentamicin qid for fourteen days. Your treatment is designed to resolve 
the ocular infection and to restore the complete health of the eye without any adverse reactions. Are you 
confident that your treatment is successful? 
Gentamicin is an antibacterial drug belonging to the aminoglycoside family. The mechanism of action is 
inhibition of bacterial protein synthesis by binding to the 30S subunit of the bacterial ribosome. Ribosomes are 
the sites of protein synthesis. The spectrum of activity includes gram-negative bacteria, and many strains of 
staphylococci (gram-positive bacteria). Most strains of streptococci bacteria are resistant to the aminoglycosides. 
Topical ocular uses include the treatment of conjunctivitis, blepharitis, meibomianitis, keratoconjunctivitis and 
dacryocystitis. When used in conjunction with another medication, it can aid in the treatment of corneal ulcers 
and orbital cellulitis. 
Upon published literature review of gentamicin, using Medline at the Pacific University Library, studies of 
adverse reactions of gentamicin were found to have been performed on either harvested or laboratory animal 
corneas using highly concentrated doses. The purpose of this study was to observe the effects of 3 mg/ml 
gentamicin on healthy, living human corneas, using the clinically acceptable and recommended dosage of four 
drops per day for fourteen days. 
Methods: 
Fifteen individuals from Pacific University College of Optometry participated in this study. These individuals 
fulfilled the criteria of having any uncompromised corneas free from trauma or disease process, intraocular 
pressure. (lOP), being pregnant, currently taking ocular medications, and not wearing contact lenses. The 
methods followed for the entire duration of the study included recording subjective responses, visual acuities, 
lOP, biomicroscopy and anterior segment photo documentation of each eye. The lOP was measured using a non-
contact (airpuff) tonometer to prevent compromise of the corneal epithelium. 
The control group of the study was the subject's right eye, while the subject's left eye served as the 
experimental group. The subjects were instructed on proper drop instillation procedures and they were 
instructed to instill one drop of gentamicin 3 mg/ml into the left eye four times a day for fourteen days. 
Evaluation on both eyes occurred on days 1, 5, 10, and 14 with a follow-up evaluation on day 16. Specified 
instillation times were one drop in the morning, lunch time, dinnertime and before bedtime. On day 14, the 
subjects discontinued instillation and returned the bottles of gentamicin. Compliance was subjectively monitored 
by verbal communication and the amount of solution remaining in the bottle. 
Results: 
The results were compiled for days 1, 5, 10, 14, and 16 using the following grading criteria for superficial 
punctate keratopathy (Fig. 1.1) with the cornea being divided into four quadrants as seen in Figure 1.2. Visual 
acuities and lOP values for all the subjects remained constant for the entire sixteen days of the experiment. 
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The day 1 data was used as the baseline for comparison of days 5, 10, 14 and 16. The quadrant exhibiting the 
most fluorescein staining in the left eye was quadrant 2 with grading types I, II and III. When compared to the 
right eye, the left eye quadrant 2 showed slightly greater staining. Differences in the remaining quadrants 
between the two eyes were statistically insignificant. (Figures 1.3, 1.4 and 1.5) 
Fig. 1.3 
Day 1 OD Ql Q2 Q3 Q4 Day 1 OS Ql 
Type 0 93.3 80 93 .3 73 .3 Type 0 86.7 
Type I 6.7 13.3 6.7 26.7 Type I 13.3 
Type II 0 6.7 0 0 Type II 0 
Type Ill 0 0 0 0 Type Ill 0 
Type IV 0 0 0 0 Type IV 0 
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Day 5 
Day 5 data showed an increase in staining in every quadrant of the left eye when compared to day l. The 
largest increase was seen in quadrant 2, types HIL This increase in staining was consistent for both eyes. There 
was an increase of 24% staining in the left eye when compared to the right. (Figures 1.6, 1. 7 and 1.8) 
Fig. 1.6 
Day 5 OD Ql QZ Q3 Q4 Day 5 OS 
Type 0 60 53.3 60 46.7 Type 0 
Type I 33.3 6.7 20 40 Type I 
Type II 6.7 13.3 0 0 Type II 
Type Ill 0 6.7 20 13.3 Type Ill 
Type IV 0 0 0 0 Type IV 
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Day 10 
Day 10 showed an increase in severity and type in all quadrants of the left eye when compared to days 1 
and 5. The largest increase in severity was in quadrant 2, showing an increase in severity from day 5 of 7 5%. 
The amount of staining in the left eye was 42% more than the right eye. The right eye showed a decrease in 
staining in quadrants 1, 3, and 4 when compared to day 5. (Figures 1.9, 1.10 and 1.11) 
Fig. 1.9 
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Day 14 
Day 14 showed an increase of 12.5% in severity and type in quadrants 2, 3, and 4 from day 10. Quadrant 1 
exhibited a decrease in severity and type. There was 43.3% more staining in the left eye when compared to the 
right eye. The right eye displayed a decrease in staining in quadrants 1, 2, and 3, while quadrant 4 remained 
unchanged. (Figures 1.1 2, 1.13 and 1.14) 
Fig. 1.12 
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Day 16 
Day 16 was a 2 day follow-up after the drops were discontinued. The data for this day displayed a decrease 
of 50.5% in severity and types in all quadrants in the left eye when compared to day 14. There was an increase 
of 23.4% of staining for the left eye in severity and types and in all quadrants, when compared to the right eye. 
There was a decrease in severity and type in all quadrants for the right eye when compared to day 14. When 
compared to the day 1 results, day 16 and day 1 results are virtually identical. (Figures 1.15, 1.16 and 1.17) 
Fig. 1.15 
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Discussion: 
The results indicate that the use of 3 mg/ ml gentamicin with a clinical dosage of 14 days qid, induces 
superficial punctate keratopathy on healthy human corneas. The corneal involvement begins to manifest as 
early as day 5. This involvement was objectively observed. The staining was most pronounced, but not limited 
to, the inferior quadrants. The quantit-y and severity of staining increased each examination time until the 
antibiotic was discontinued. The only significant subjective response given by one subject was, "My vision is 
hazy, with a foreign body sensation." The subject discontinued the gentamicin drops and was treated vvith 
carboxymethylcellulose sodium 1%. The subject's vision resumed clarity 30 minutes after the treatment with 
carboxymethylcellulose instillation. The foreign body sensation subsided after two days following 
carboxymethylcellulose treatment. With the exception of this one subject, the corneal involvement did not 
interfere with clarity of vision. The superficial punctate keratitis never exhibited loss of epithelial tissue (type 
IV superficial punctate keratopathy). After the drops were discontinued for two days, the superficial punctate 
keratopathy staining was minimal and resembled the day one results. Uncontrollable factors that may have 
contributed to the subjects having superficial punctate keratopathy staining were not controllable included 
exposure to second-hand smoke, foreign bodies, systemic illness and unknown. allergies. Subjective complaints 
listed above were taken under consideration when the corneas were evaluated. One other factor that may have 
influenced the results was the preservative benzalkonium chloride 0.01% due to rare hypersensitivity in some 
individuals. Further testing is needed to rule out possible benzalkonium chloride hypersensitivity that may lead 
to corneal degradation is needed. 
Conclusion: 
The usage of clinically acceptable and recommended doses of gentamicin induces the formation of superficial 
punctate keratopathy. The formation of the superficial punctate keratopathy developed by day 5 and continued 
to increase until the discontinuation of the drops. After 2 days of drop discontinuation, the integrity of the 
corneal epithelium was found to be similar to the pre-drop findings for all the subjects. Whether the corneal 
superficial punctate keratopathy was produced by either the aminoglycoside, the benzalkonium chloride, or a 
combination of both, our conclusions are that the Bausch & Lomb product, gentamicin, does produce superficial 
punctate keratopathy formation on healthy human corneas if used longer than 5 days. 
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